Introduction
The Holy Grail for HIV research activities is the elimination of virus from an infected human host. Notwithstanding prodigious research efforts, vaccination has so far failed, and combination antiretroviral therapy (cART) has permitted low-level persistent viral replication. The latter is observed in defined reservoirs with notable disease morbidities. One such morbidity is central nervous system (CNS) disease, which affects cognitive, behavioral and motor functions that trigger a range of adverse clinical outcomes. Up to 27% of HIV-1-infected people show identifiable cognitive dysfunction, and 84% show definable deficits in cognition, physiology and behavior [1] . The clinical manifestations of HIV-associated neurocognitive disorders (HAND), interestingly, range from very limited deficits in information processing to profound dementia [2] [3] [4] . Brain pathology ranges from limited discernable abnormalities to multinucleated giant cell encephalitis [5] . Research activities serve to improve diagnosis, understand disease processes, and improve drug delivery and therapeutics. These can best be achieved through experimental systems that reflect chronic viral infection and neuronal function [6] .
HIV targets brain mononuclear phagocytes (MPs; monocyte-derived macrophages and microglia) and immune suppression speeds virus growth and related neuronal injuries. Viral and cellular MP products elicit local metabolic dysfunctions and disrupt neuronal networks. Paracrine regulations of immune secreted bioactive products (e.g. chemokines, cytokines, arachidonic metabolites, quinolinic acid, Fas and Fas ligand among others) induce inflammation and affect disease tempo [7] . How systemic infection, immune activation and nervous system infection drive neuronal damage can be addressed through relevant animal models [8, 9] . The following are important requirements for reflecting HAND in animals. First, an animal model should provide virus-susceptible target cells, including CD4 + T lymphocytes, dendritic cells, monocytes and macrophages, that display receptors and coreceptors for viral infection and possess the host cell machinery to complete the viral life-cycle. Second, animals need to be infected through known portals of virus entry (i.e. the genitourinary system, rectum and blood). Third, infection and immune activation need be continuous for prolonged time-periods to model the chronic nature of disease. Fourth, BBB function should be altered as a consequence of viral infection to permit leukocyte transmigration. Fifth, virus target cells in the nervous system and viral reservoirs need be maintained. Here, we review recent progress in the development of rodent models that fulfill many of these requirements and, as such, provide an important means to study the pathophysiology of HAND. The noted limitations of the models together with the pathways towards improvements are discussed.
Animal models of lentiviral infections
HIV is a lentivirus and any review of animal models of HAND must take into consideration the unique molecular and biological properties of lentiviruses. Since the first appearance of the acquired immunodeficiency syndrome (AIDS) and the discovery of its causative agent, HIV, laboratory and animal models were quickly generated which mimic human disease. In particular, models that reflected viral neuropathologies and pneumonitis were sought because lentivirus infections commonly cause such tissue injuries as a result of persistent replication in MPs [10, 11] 
